Current clinical trials with CAR-T cells in AML patients address CD33, CD123, CLL-1, CD44v6, and NKG2D as target molecules expressed on AML, while conditioning therapy prior to CAR-T cell application is similar to lymphodepletion regularly administered in lymphoma patients [159]. This evidence concerns the gene KLRK1 and acute myeloid leukemia.